Osmotica Pharmaceuticals PLC (OSMT)
| Market Cap | 206.97M |
| Revenue (ttm) | 153.12M |
| Net Income (ttm) | -86.12M |
| Shares Out | 62.68M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $3.31 |
| Previous Close | $3.33 |
| Change ($) | -0.02 |
| Change (%) | -0.60% |
| Day's Open | 3.33 |
| Day's Range | 3.27 - 3.35 |
| Day's Volume | 41,379 |
| 52-Week Range | 2.70 - 6.49 |
BRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J. Aaron ...
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has agreed to sell its portfolio of legacy products and Georgia manufacturing facility, for up to $170 million, to Alora Pharmaceuticals LLC. Osmotica will re...
Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone payments Alora will acquire manufacturing operations in Marietta, Georg...
BRIDGEWATER, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced results of t...
BRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Ma...
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 34.78% and -25.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Ma...
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies
BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Comp...
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT). Such in...
Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased after the company reported Q4 results. Quarterly Results Earnings per share decreased 1566.67% over the past year to ($0.88), which missed the ...
Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively
BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Co...
BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian ...
BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...
BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9
BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9
BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
One of the company's pipeline candidates ran into a regulatory hurdle.
BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issu...
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...
Adamas to acquire global rights to OSMOLEX ER® for $7.5 million
-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL's commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D., PhD, fur...
BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...
Osmotica Pharmaceuticals' (OSMT) CEO Brian Markison on Q3 2020 Results - Earnings Call Transcript
Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) rose 4.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 148.28% year over year to ($0.14)...
Third quarter 2020 total revenue of $57.2 million
BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Com...
-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis...
BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Bria...
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased 4.46% in after-market trading after the company reported Q2 results.
Second quarter 2020 total revenue of $37.5 million
-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-
OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (...
BRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully integrated...
The company announced the pricing of a public offering of common stock.
BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricin...
BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commen...
Osmotica Pharmaceuticals (NASDAQ: OSMT) surged Friday, ending the day up 25.3% to close at $8.77 per share.
One of the company’s promising products was approved by the FDA.
-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and ...
-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80 mg/day --
Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
About OSMT
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol OSMT |
Financial Performance
In 2020, OSMT's revenue was $177.88 million, a decrease of -25.89% compared to the previous year's $240.03 million. Losses were -$79.59 million, -70.62% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for OSMT stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 126.59% from the latest price.